ATXN2 Trinucleotide Repeat Length Correlates with Risk of ALS

We investigated a CAG trinucleotide repeat expansion in the ATXN2 gene in amyotrophic lateral sclerosis (ALS). Two new case-control studies, a British dataset of 1474 ALS cases and 567 controls, and a Dutch dataset of 1328 ALS cases and 691 controls were analyzed. In addition, to increase power, we systematically searched PubMed for case-control studies published after 1 August 2010 that investigated the association between ATXN2 intermediate repeats and ALS. We conducted a meta-analysis of the new and existing studies for the relative risks of ATXN2 intermediate repeat alleles of between 24 and 34 CAG trinucleotide repeats and ALS. There was an overall increased risk of ALS for those carrying intermediate sized trinucleotide repeat alleles (odds ratio 3.06 [95% confidence interval 2.37-3.94]; p = 6 × 10), with an exponential relationship between repeat length and ALS risk for alleles of 29-32 repeats (R = 0.91, p = 0.0002). No relationship was seen for repeat length and age of onset or survival. In contrast to trinucleotide repeat diseases, intermediate ATXN2 trinucleotide repeat expansion in ALS does not predict age of onset but does predict disease risk.

Citing Articles

Tandem repeat expansions and copy number variations as risk factors and diagnostic tools for amyotrophic lateral sclerosis.

Sabetta E, Ferrari D, Massimo L, Koks S Front Neurol. 2025; 16:1522445.

PMID: 40012994 PMC: 11860076. DOI: 10.3389/fneur.2025.1522445.

An observational study of pleiotropy and penetrance of amyotrophic lateral sclerosis associated with CAG-repeat expansion of ATXN2.

Demaegd K, Kernan A, Cooper-Knock J, van Vugt J, Harvey C, Moll T Eur J Hum Genet. 2025; .

PMID: 39956874 DOI: 10.1038/s41431-025-01811-2.

Co-Aggregation of TDP-43 with Other Pathogenic Proteins and Their Co-Pathologies in Neurodegenerative Diseases.

Jiang L, Zhang X, Hu H Int J Mol Sci. 2024; 25(22).

PMID: 39596445 PMC: 11594478. DOI: 10.3390/ijms252212380.

Altered mRNA transport and local translation in iNeurons with RNA binding protein knockdown.

Dargan R, Mikheenko A, Johnson N, Packer B, Li Z, Craig E bioRxiv. 2024; .

PMID: 39386562 PMC: 11463369. DOI: 10.1101/2024.09.26.615153.

Genome-wide association study of copy number variations in Parkinson's disease.

Landoulsi Z, Ashok Kumar Sreelatha A, Schulte C, Bobbili D, Montanucci L, Leu C medRxiv. 2024; .

PMID: 39228715 PMC: 11370542. DOI: 10.1101/2024.08.21.24311915.

References

Tezenas du Montcel S, Durr A, Bauer P, Figueroa K, Ichikawa Y, Brussino A . Modulation of the age at onset in spinocerebellar ataxia by CAG tracts in various genes. Brain. 2014; 137(Pt 9):2444-55. PMC: 4132646. DOI: 10.1093/brain/awu174. View

Abel O, Powell J, Andersen P, Al-Chalabi A . ALSoD: A user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum Mutat. 2012; 33(9):1345-51. DOI: 10.1002/humu.22157. View

Jin P, Warren S . Understanding the molecular basis of fragile X syndrome. Hum Mol Genet. 2000; 9(6):901-8. DOI: 10.1093/hmg/9.6.901. View

Lattante S, Millecamps S, Stevanin G, Rivaud-Pechoux S, Moigneu C, Camuzat A . Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disorders. Neurology. 2014; 83(11):990-5. PMC: 4162303. DOI: 10.1212/WNL.0000000000000778. View

Van Damme P, Veldink J, van Blitterswijk M, Corveleyn A, van Vught P, Thijs V . Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology. 2011; 76(24):2066-72. DOI: 10.1212/WNL.0b013e31821f445b. View

Koeppen A . Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci. 2011; 303(1-2):1-12. PMC: 3062632. DOI: 10.1016/j.jns.2011.01.010. View

Lahut S, Omur O, Uyan O, Agim Z, Ozoguz A, Parman Y . ATXN2 and its neighbouring gene SH2B3 are associated with increased ALS risk in the Turkish population. PLoS One. 2012; 7(8):e42956. PMC: 3423429. DOI: 10.1371/journal.pone.0042956. View

Gispert S, Kurz A, Waibel S, Bauer P, Liepelt I, Geisen C . The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiol Dis. 2011; 45(1):356-61. DOI: 10.1016/j.nbd.2011.08.021. View

Gellera C, Ticozzi N, Pensato V, Nanetti L, Castucci A, Castellotti B . ATAXIN2 CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? Implication for genetic testing and counseling. Neurobiol Aging. 2012; 33(8):1847.e15-21. DOI: 10.1016/j.neurobiolaging.2012.02.004. View

10.

Liu X, Lu M, Tang L, Zhang N, Chui D, Fan D . ATXN2 CAG repeat expansions increase the risk for Chinese patients with amyotrophic lateral sclerosis. Neurobiol Aging. 2013; 34(9):2236.e5-8. DOI: 10.1016/j.neurobiolaging.2013.04.009. View

11.

Kayatekin C, Matlack K, Hesse W, Guan Y, Chakrabortee S, Russ J . Prion-like proteins sequester and suppress the toxicity of huntingtin exon 1. Proc Natl Acad Sci U S A. 2014; 111(33):12085-90. PMC: 4143035. DOI: 10.1073/pnas.1412504111. View

12.

Kim J, Hong S, Kim G, Choi Y, Kim Y, Park S . Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism. Arch Neurol. 2007; 64(10):1510-8. DOI: 10.1001/archneur.64.10.1510. View

13.

Soraru G, Clementi M, Forzan M, Orsetti V, DAscenzo C, Querin G . ALS risk but not phenotype is affected by ataxin-2 intermediate length polyglutamine expansion. Neurology. 2011; 76(23):2030-1. DOI: 10.1212/WNL.0b013e31821e557a. View

14.

Wang M, Gomes J, Cashman N, Little J, Krewski D . Intermediate CAG repeat expansion in the ATXN2 gene is a unique genetic risk factor for ALS--a systematic review and meta-analysis of observational studies. PLoS One. 2014; 9(8):e105534. PMC: 4141758. DOI: 10.1371/journal.pone.0105534. View

15.

Yu Z, Zhu Y, Chen-Plotkin A, Clay-Falcone D, McCluskey L, Elman L . PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats. PLoS One. 2011; 6(3):e17951. PMC: 3066214. DOI: 10.1371/journal.pone.0017951. View

16.

van Rheenen W, Shatunov A, Dekker A, McLaughlin R, Diekstra F, Pulit S . Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet. 2016; 48(9):1043-8. PMC: 5556360. DOI: 10.1038/ng.3622. View

17.

Chio A, Calvo A, Moglia C, Canosa A, Brunetti M, Barberis M . ATXN2 polyQ intermediate repeats are a modifier of ALS survival. Neurology. 2014; 84(3):251-8. DOI: 10.1212/WNL.0000000000001159. View

18.

Corrado L, Mazzini L, Oggioni G, Luciano B, Godi M, Brusco A . ATXN-2 CAG repeat expansions are interrupted in ALS patients. Hum Genet. 2011; 130(4):575-80. DOI: 10.1007/s00439-011-1000-2. View

19.

Paulsen J, Long J, Ross C, Harrington D, Erwin C, Williams J . Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study. Lancet Neurol. 2014; 13(12):1193-201. PMC: 4373455. DOI: 10.1016/S1474-4422(14)70238-8. View

20.

Fernandez M, McClain M, Martinez R, Snow K, Lipe H, Ravits J . Late-onset SCA2: 33 CAG repeats are sufficient to cause disease. Neurology. 2000; 55(4):569-72. DOI: 10.1212/wnl.55.4.569. View